XORTX Therapeutics Inc. Common Shares (XRTX)
Stock · NASDAQ · Health Care
$1.24as of 10/16/2026
Price chart
Active signals
XRTX Signal Track Record
How signals performed across all stocks →What XRTX's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Bollinger Band Breakdown | 25 | +2.6% | 60% | October 9, 2026 |
| Bollinger Band Breakout | 20 | -18.6% | 15% | August 25, 2026 |
| Volume Spike | 13 | -13.4% | 23% | October 8, 2026 |
| 200-Day Moving Average TouchActive now | 4 | -21.0% | 0% | August 27, 2026 |
| Any 20-session window (baseline) | -6.8% | 32% |
Computed by MarketWall from daily closing prices since July 11, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About XRTX
XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat hyperuricemia related diseases in Canada. It develops XRx-026, which is in Phase III for the treatment of gout; XRx-008, which is in Phase II for the treatment of autosomal dominant polycystic kidney disease; XRx-101, which is in Phase II for the treatment of acute kidney injur…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Website
- www.xortx.com/
Fundamentals
- 1-day range
- $1.41$1.54
- Market cap
- $3.51M
- P/E (trailing)
- —
- P/E (forward)
- 1.77
- EPS (trailing)
- $-2.65
- Dividend yield
- —
- Beta
- 0.03
- Avg. volume
- 714.2K
XORTX Therapeutics Inc. Common Shares Competitors
Chosen by industry and closest market cap.
- XRTXXORTX Therapeutics Inc. Common Shares$1.24▼ 12.68%Market cap $3.51MP/E —$2.42$9.85
- RDHLRedhill Biopharma Ltd. American Depositary Shares$0.48▼ 3.81%Market cap $3.53MP/E Infinity$0.4351$2.14
- PRFXPRF Technologies Ltd. Ordinary Shares$0.781▼ 7.68%Market cap $3.35MP/E —$0.8099$7.95
- ONCOOnconetix Inc. Common Stock$0.479▼ 12.59%Market cap $3.34MP/E 0.00$0.535$200
- SXTP60 Degrees Pharmaceuticals Inc. Common Stock$0.855▼ 4.89%Market cap $3.28MP/E —$0.835$8.62
- SPRCSciSparc Ltd. Ordinary Shares$1.7▼ 15.00%Market cap $3.85MP/E —$1.63$43.65
- MBIOMustang Bio Inc. Common Stock$0.376▼ 2.59%Market cap $3.87MP/E —$0.3701$1.69
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| XRTX XORTX Therapeutics Inc. Common Shares | $3.51M | — | $1.24 | ▼ 12.68% | $2.42$9.85 |
| RDHL Redhill Biopharma Ltd. American Depositary Shares | $3.53M | Infinity | $0.48 | ▼ 3.81% | $0.4351$2.14 |
| PRFX PRF Technologies Ltd. Ordinary Shares | $3.35M | — | $0.781 | ▼ 7.68% | $0.8099$7.95 |
| ONCO Onconetix Inc. Common Stock | $3.34M | 0.00 | $0.479 | ▼ 12.59% | $0.535$200 |
| SXTP 60 Degrees Pharmaceuticals Inc. Common Stock | $3.28M | — | $0.855 | ▼ 4.89% | $0.835$8.62 |
| SPRC SciSparc Ltd. Ordinary Shares | $3.85M | — | $1.7 | ▼ 15.00% | $1.63$43.65 |
| MBIO Mustang Bio Inc. Common Stock | $3.87M | — | $0.376 | ▼ 2.59% | $0.3701$1.69 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- These stocks are moving in today's sessionChartMill · 10/9/2026
- 12 Health Care Stocks Moving In Friday's After-Market SessionBenzinga · 10/9/2026
- 12 Health Care Stocks Moving In Friday's Intraday SessionBenzinga · 10/9/2026
- These stocks are moving in today's pre-market sessionChartMill · 10/9/2026
- 12 Health Care Stocks Moving In Friday's Pre-Market SessionBenzinga · 10/9/2026
- XORTX Therapeutics (XRTX) Stock Jumps Over 22% After Hours: Here's WhyBenzinga · 10/9/2026
- What's going on in today's after hours sessionChartMill · 10/8/2026
- XORTX Outlines Anticipated Health Canada Clinical Trial Application for XRx-026 for GoutYahoo · 10/8/2026
Institutional Ownership
March 31, 2026
- Total shares held
- 15.3K
- Total value held
- $6.2K
- Institutional holders
- 2
- Unknown15.0K
- Unknown277
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 9, 2026
XRTX Jumps 22% on Gout Trial Plans
XORTX Therapeutics shares rose more than 22% after hours following an announcement outlining a planned Health Canada clinical trial application for its drug XRx-026, which targets gout. This development marks a significant step in the company's pipeline and drove the sharp price movement. The stock remains well below its 52-week high, reflecting the volatility typical of smaller biotech firms.
XRTX Jumps 22% on Gout Trial Plans. XORTX Therapeutics shares rose more than 22% after hours following an announcement outlining a planned Health Canada clinical trial application for its drug XRx-026, which targets gout. This development marks a significant step in the company's pipeline and drove the sharp price movement. The stock remains well below its 52-week high, reflecting the volatility typical of smaller biotech firms.